4//SEC Filing
Xenon Pharmaceuticals Inc. 4
Accession 0001209191-14-068354
$XENECIK 0001582313operating
Filed
Nov 11, 7:00 PM ET
Accepted
Nov 12, 8:43 PM ET
Size
8.2 KB
Accession
0001209191-14-068354
Insider Transaction Report
Form 4
Evans Johnston L
Director
Transactions
- Conversion
Series E Preferred Shares
2014-11-09−444,655→ 0 total(indirect: By Invesco Capital Entities)→ Common Shares (444,655 underlying) - Conversion
Common Shares
2014-11-09+444,655→ 444,655 total(indirect: By Invesco Capital Entities)
Footnotes (2)
- [F1]The Series E Preferred Shares converted into Common Shares on a 1.2-for-1 basis immediately prior to the completion of the Issuer's initial public offering of Common Shares and had no expiration date.
- [F2]Consists of (i) 264,349 shares held by Chancellor V, L.P. ("Chancellor V"); (ii) 138,644 shares held by Chancellor V-A, L.P. ("Chancellor V-A"); and (iii) 41,662 shares held by Citiventure 2000, L.P. ("Citiventure"). Invesco Private Capital, Inc. is the managing member of IPC Direct Associates V, LLC, which is a Managing Director of each of Chancellor V, Chancellor V-A and Citiventure (collectively referred to as the "Invesco Capital Entities"). Mr. Evans is the Head of Invesco Private Capital, Inc. and a member of the investment committee of IPC Direct Associates V, LLC. Accordingly, Mr. Evans shares voting and investment power of the shares held by the Invesco Capital Entities. Mr. Evans disclaims beneficial ownership of these shares except with respect to his pecuniary interest therein
Documents
Issuer
Xenon Pharmaceuticals Inc.
CIK 0001582313
Entity typeoperating
IncorporatedBritish Columbia, Canada
Related Parties
1- filerCIK 0001582313
Filing Metadata
- Form type
- 4
- Filed
- Nov 11, 7:00 PM ET
- Accepted
- Nov 12, 8:43 PM ET
- Size
- 8.2 KB